Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
XERS

XERS - Xeris Pharmaceuticals Inc Stock Price, Fair Value and News

$6.80-0.13 (-1.88%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

63/100

XERS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

63/100

XERS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

XERS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XERS Price Action

Last 7 days

10.0%

Last 30 days

5.8%

Last 90 days

24.5%

Trailing 12 Months

53.9%

XERS RSI Chart

XERS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XERS Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

97.72

Price/Sales (Trailing)

3.73

EV/EBITDA

37.23

Price/Free Cashflow

24.18

XERS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

XERS Fundamentals

XERS Revenue

Revenue (TTM)

314.9M

Rev. Growth (Yr)

38.27%

Rev. Growth (Qtr)

-3.12%

XERS Earnings

Earnings (TTM)

12.0M

Earnings Growth (Yr)

124.23%

Earnings Growth (Qtr)

-79.84%

XERS Profitability

EBT Margin

0.18%

Return on Equity

92.29%

Return on Assets

3.06%

Free Cashflow Yield

4.14%

XERS Investor Care

Shares Dilution (1Y)

10.60%

Diluted EPS (TTM)

0.07

XERS Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2026314.9M000
2025222.6M246.0M266.1M291.8M
2024171.4M181.4M187.4M203.1M
2023121.4M134.1M152.7M163.9M
202263.5M79.9M98.5M110.2M
202127.7M35.0M42.3M49.6M
202000020.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Xeris Pharmaceuticals Inc

XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
 CEO
 WEBSITExerispharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES355

Xeris Pharmaceuticals Inc Frequently Asked Questions

XERS is the stock ticker symbol of Xeris Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Xeris Pharmaceuticals Inc is 1.17 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, XERS's PE ratio (Price to Earnings) is 97.72 and Price to Sales (PS) ratio is 3.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XERS PE ratio will change depending on the future growth rate expectations of investors.